Table 4.

Conditional logistic regression model for delays in completion of anti-tuberculosis treatment

Characteristic	Cases (n = 253) n (%)	Controls (n = 253) n (%)	Unadjusted OR (95%CI)	P value	Adjusted OR (95%CI)	P value
Male sex	178 (70.4)	170 (67.2)	1.16 (0.80–1.68)	0.45	1.25 (0.73–2.11)	0.41
Black, non-Hispanic race	230 (90.9)	226 (89.3)	1.24 (0.65–2.34)	0.52	0.76 (0.27–2.09)	0.60
US-born	211 (83.4)	195 (77.1)	1.57 (0.98–2.52)	0.06	1.23 (0.54–2.79)	0.63
Homeless	30 (11.9)	22 (8.7)	1.42 (0.79–2.56)	0.24	1.58 (0.70–3.77)	0.31
Correctional facility	21 (8.3)	14 (5.5)	1.78 (0.79–4.02)	0.17	1.78 (0.65–4.86)	0.26
HIV infection	31 (12.2)	19 (7.5)	1.80 (0.96–3.38)	0.07	2.10 (0.85–5.22)	0.11
Substance use (alcohol and/or illicit drugs)	78 (30.8)	78 (30.8)	1.00 (0.65–1.53)	1.00	0.36 (0.15–0.90)*	0.03*
Tobacco use	146 (57.7)	136 (53.7)	1.20 (0.82–1.73)	0.34	0.71 (0.39–1.29)	0.26
Extra-pulmonary disease	72 (28.5)	61 (21.1)	1.27 (0.84–1.93)	0.25	1.75 (1.00–3.05)	0.05
Cavitary disease and culture-positive at 2 months	35 (13.8)	11 (4.3)	4.00 (1.84–8.68)*	<0.001*	5.85 (1.98–17.32)*	0.001*
Any SAT	98 (38.7)	98 (38.7)	1.00 (0.60–1.67)	1.00	0.65 (0.33–1.30)	0.22
Non-adherent	91 (36.0)	36 (14.2)	4.06 (2.42–6.79)*	<0.001*	4.13 (1.76–9.72)*	0.001*
Drug-related treatment interruptions	115 (45.4)	29 (11.5)	6.09 (3.63–10.12)*	<0.001*	6.91 (3.76–12.70)*	<0.001*
Medical comorbidities	104 (41.1)	74 (29.2)	1.86 (1.23–2.80)*	0.003*	1.24 (0.71–2.17)	0.45

^*Statistically significant.

OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus; SAT = self-administered therapy.